Efficacy and safety of duvakitug in patients with Crohn's disease (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial.
Lancet Gastroenterol HepatolJul 16, 2026 (epub)
Clinical ResearchGastroenterology
Vipul Jairath, Jaroslaw Kierkuś, George Aaron Duvall et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 2b, randomized, placebo-controlled trial evaluated the efficacy and safety of duvakitug in adults with moderately to severely active Crohn's disease. Among 139 enrolled patients, endoscopic response at week 14 was observed in 48% of those receiving duvakitug 900 mg compared to 13% in the placebo group, indicating significant efficacy.
Key findings
- 48% of patients in the duvakitug 900 mg group achieved endoscopic response at week 14.
- The difference in response rates versus placebo was 33% for duvakitug 900 mg.
- 67% of patients in the duvakitug 450 mg group experienced adverse events.
- Serious adverse events occurred in 13% of the duvakitug 450 mg group.
Why it matters
The findings suggest that duvakitug may provide a new therapeutic option for patients with Crohn's disease who have not responded adequately to existing treatments, potentially improving patient outcomes.